MaxCyte (MXCT) Q2 FY26 earnings call

MaxCyte reported Q2 FY26 results ahead of expectations, demonstrating revenue stabilization and sequential growth driven by instrument placements. The company secured a significant multi-platform partnership with Genentech, marking an evolution in its commercial strategy to include enterprise-level agreements alongside traditional SPLs. Despite year-over-year revenue declines and gross margin pressure from product mix, disciplined cost management and share repurchases underscore a focus on financial health, with management confident in a return to revenue growth in the second half of the year.